Navigation Links
Team discovers new inhibitors of estrogen-dependent breast cancer cells
Date:6/16/2008

Researchers have discovered a new family of agents that inhibit the growth of estrogen-dependent breast cancer cells. The finding, described today at a meeting of the Endocrine Society, has opened an avenue of research into new drugs to combat estrogen-dependent breast cancers.

"This cell-based study is exciting because it suggests these compounds are likely to be effective in tumors that remain dependent on estrogen for growth but are resistant to current therapies," said principal investigator David J. Shapiro, a professor of biochemistry in the School of Molecular and Cellular Biology at the University of Illinois.

Although multiple factors contribute to the development of breast cancer, estrogens play a key role in the growth of many tumors. More than 80 percent of breast cancer tumors in women over age 45 are activated by estrogen by way of a protein called an estrogen receptor. When estrogen binds to the receptor, this "estrogen-receptor complex" latches on to DNA and prompts it to transcribe the RNA blueprints for new proteins that promote cell growth, migration and division.

Current therapies for estrogen-receptor-positive (ER-positive) breast cancers include the use of drugs, such as tamoxifen, that interfere with estrogen's ability to bind to the estrogen receptor. Over time, however, ER-positive breast cancer tumors become resistant to tamoxifen. In some resistant tumors, tamoxifen even begins to act like estrogen and actually stimulates tumor growth.

"Tamoxifen is useful in that it is very effective at blocking recurrence of breast cancer in patients for whom the entire tumor is removed," Shapiro said. "But for patients who still have existing tumors, eventually those tumors will become resistant."

Shapiro's team sought to target other steps in the pathway of estrogen action. Using a technique they developed that can quickly determine whether the target DNA is or is not bound by the estrogen-receptor co
'/>"/>

Contact: Diana Yates
diya@illinois.edu
217-333-5802
University of Illinois at Urbana-Champaign
Source:Eurekalert

0

GOOD

Page: 1 2

Related medicine news :

1. OHSU Cancer Institute researcher discovers what fuels certain cancer mutation
2. Research discovers new compounds active against tuberculosis and malaria
3. OHSU cancer institute researcher discovers new predictor of prostate cancer recurrence
4. NYU dental professor discovers biological clock
5. U of Minnesota researcher discovers the starting point of sun-induced skin cancer
6. Silencing small but mighty cancer inhibitors
7. Effect of tumor necrosis factor a inhibitors on heart failure risk in RA Patients
8. NSAIDs: Painkillers, inflammation inhibitors, anti-cancer drugs and new de-methylating agents
9. Gastric juice for diagnosis of H. pylori infection in patients on proton pump inhibitors
10. FDA Approves NOVO NORDISKs NovoSeven(R) RT (Coagulation Factor VIIa [Recombinant] Room Temperature Stable) for Hemophilia Patients With Inhibitors
11. Survival differences by race most apparent in advanced stages of breast cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/20/2013)... CosmosID, a leading data mining solutions company for health ... results on analysis of labeling claims for the composition ... The Food and Drug Administration (FDA) and CosmosID conducted ... four of which have been reported at the American ... was to compare the identity of species and strains ...
(Date:5/20/2013)... Sporturf, an international manufacturer and builder of synthetic ... Midwest with the opening of the company’s third regional ... is under the leadership of President Craig Shonk, and ... , “This strategic move opens up a market ... Shonk. “Bringing an ISO manufacturer and a Midwest-based ASBA ...
(Date:5/20/2013)... Online education provides the convenience, flexibility and cost-saving ... According to the American Heart Association, 27% of ... to eLearning due to changing economic conditions. The ... budgets, but it is also proven to enhance ... higher retention of content is probable, given the ...
(Date:5/20/2013)... as a consequence of diabetic foot ulcer that does ... this situation are very limited. In his doctoral thesis ... Department of Medical Biochemistry and Biophysics at Ume University ... may completely change the lives of millions of patients. ... chronic wounds that largely impair the quality of life ...
(Date:5/20/2013)... (PRWEB) May 20, 2013 BenefitMall, ... of employee benefit, payroll products and services and ... both are selected as finalists for the 2013 American ... Company of the Year category, and CompuPay is a ... finalist will ultimately be a Gold, Silver or Bronze ...
Breaking Medicine News(10 mins):Health News:CosmosID unveils new tool for faster, specific and accurate testing of probiotics products 2Health News:Sporturf Expands into the Midwestern U.S. 2Health News:Swank HealthCare Announces New Offering of Additional American Heart Association’s Accredited Online Courses 2Health News:Discovery of a novel medicine for the treatment of chronic wounds 2Health News:BenefitMall And CompuPay, Inc., A BenefitMall Company, Named As Finalists In 2013 American Business Awards 2Health News:BenefitMall And CompuPay, Inc., A BenefitMall Company, Named As Finalists In 2013 American Business Awards 3
... September 9, 2010 Amyloid beta (Αβ) proteins, ... transport of vital cargoes inside brain cells. Scientists at ... that reducing the level of another protein, tau, can ... in the brain are connected to many other neurons ...
... of the Hastings Center Report ... to legalize physician-assistance in dying, either do not participate ... assistance. Both legal and moral reasons are identified. ... for assuring that physician-assisted death is carried out responsibly, ...
... By Randy Dotinga HealthDay Reporter , THURSDAY, Sept. ... quick MRI scan could tell doctors if a child,s brain ... mental problems are developing. Researchers say the strategy could ... the age-old growth charts that tell pediatricians if kids are ...
... Amsterdam, The Netherlands, September 2010 More than ... all over the world met at the 23rd Congress of ... 1 September 2010 in Amsterdam. The ECNP Congress is ... this year included 46 sessions presented by ...
... Virginia Commonwealth University Medical Center is the lead institution in ... heart patients to recuperate, rehabilitate and wait in the comfort ... for transplant. , The VCU Pauley Heart Center is one ... mechanical driver that can power patients, artificial hearts and enable ...
... the world,s population is infected with Mycobacterium tuberculosis (MTB), ... death world-wide. A new discovery, led by a team ... Medicine, offers hope for new approaches to the prevention ... novel mechanism that may contribute to immune recognition of ...
Cached Medicine News:Health News:Strategy discovered to prevent Alzheimer's-associated traffic jams in the brain 2Health News:Study finds most Oregon hospices do not fully participate in the Death with Dignity Act 2Health News:Brain Scans Could Spot Developmental Problems in Kids 2Health News:23rd ECNP Congress: Europe's largest scientific meeting on mental health 2Health News:VCU Medical Center leads study of first US portable driver for powering the total artificial heart 2Health News:New dual recognition mechanism discovered in tuberculosis 2Health News:New dual recognition mechanism discovered in tuberculosis 3
(Date:5/20/2013)... ALISO VIEJO , Kalifornien, 20. Mai ... heute bekannt, dass das Unternehmen die CE-Kennzeichnung ... Implantate zur Embolisation von Aneurysmen erhalten hat. ... in Europa bereits mit der kontrollierten Einführung ... Profil bietet die SL-Produktfamilie auch ein verbessertes ...
(Date:5/20/2013)... Enrollment of patients with Type 2 diabetes ... trial of product candidate NewMet ™, a delayed-release ... 2 diabetes. Elcelyx expects to complete enrollment of 240 ... of the trial,s primary endpoint of change in fasting ... read-out for long-term glucose lowering and weight benefits is ...
(Date:5/20/2013)... 20, 2013  AbbVie (NYSE: ABBV ... 3 clinical study called SONAR (Study Of Diabetic ... the investigational compound atrasentan - when added to standard ... patients with stage 2 to 4 chronic kidney ... a large, multinational, double-blind, placebo-controlled clinical study that ...
Breaking Medicine Technology:Sequent Medical, Inc. bringt neue SL-Produktfamilie seiner WEB Geräte zur Embolisation von Aneurysmen auf den Markt 2Sequent Medical, Inc. bringt neue SL-Produktfamilie seiner WEB Geräte zur Embolisation von Aneurysmen auf den Markt 3Elcelyx Therapeutics Enrolling Phase 2b Trial of NewMet for Type 2 Diabetes 2Elcelyx Therapeutics Enrolling Phase 2b Trial of NewMet for Type 2 Diabetes 3Elcelyx Therapeutics Enrolling Phase 2b Trial of NewMet for Type 2 Diabetes 4AbbVie Initiates Phase 3 Study of Its Investigational Compound Atrasentan on Renal Outcomes in Patients with Diabetic Nephropathy 2AbbVie Initiates Phase 3 Study of Its Investigational Compound Atrasentan on Renal Outcomes in Patients with Diabetic Nephropathy 3AbbVie Initiates Phase 3 Study of Its Investigational Compound Atrasentan on Renal Outcomes in Patients with Diabetic Nephropathy 4AbbVie Initiates Phase 3 Study of Its Investigational Compound Atrasentan on Renal Outcomes in Patients with Diabetic Nephropathy 5AbbVie Initiates Phase 3 Study of Its Investigational Compound Atrasentan on Renal Outcomes in Patients with Diabetic Nephropathy 6
This portable resource provides definitions for medical acronyms and abbreviations....
English and Spanish translations of all medical terms and phrases used in clinician-patient interactions....
... This Mobile Solution (Palm OS) makes ... patient visit information functionality of the ... (PDA). You'll save time and have access ... at your desktop - review appointment schedules, ...
Preferred Health Resourses Practice Management System is called Remedy. The PDA version is Remedy for the Palm. It is a data capture program for your medical billing....
Medicine Products: